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Abstract
Clinical obervations indicate that antipsychotic action starts early and increases in magnitude with repeated treatment. Animal
models that faithfully capture this time course of action are few. Inhibition of hyperlocomotion induced by amphetamine or
phencyclidine has been widely used as a screening tool for the antipsychotic activity of a drug. We thus investigated whether
repeated antipsychotic treatment could produce an early-onset and progressively increased antagonistic effect on amphetamine
or phencyclidine-induced hyperlocomotion as a way of assessing the validity of such models in capturing time course of antipsychotic action. One each of the five consecutive test days, different groups of rats (n = 6-7/group) received an initial injection of
either haloperidol (0.01-0.10 mg/kg, sc), clozapine (5-20.0 mg/kg, sc), olanzapine (1.0 mg/kg, sc), chlordiazepoxide (10.0 mg/
kg, ip) or vehicle (sterile water, sc) 30 min prior to a second injection of either amphetamine (1.5 mg/kg, sc) or phencyclidine (3.2
mg/kg, sc). Motor activity was subsequently monitored for 60 min after amphetamine or phencyclidine treatment. Repeated
treatment of haloperidol, clozapine, or olanzapine progressively potentiated inhibition on repeated phencyclidine-induced
hyperlocomotion and prolonged this action over the five consecutive days. In contrast, antipsychotic inhibition on repeated
amphetamine-induced hyperlocomotion was gradually attenuated and shortened. Repeated treatment of chlordiazepoxide, a
benzodiazepine anxiolytic, retained its inhibition on amphetamine-induced hyperlocomotion, but had no effect on phencyclidine-induced one. These results suggest that repeated phencyclidine-induced hyperlocomotion model based on repeated antipsychotic treatment regimen is capable of capturing the progressive increase pattern of antipychotic treatment seen in the clinic
and differentiating antipsychotics from anxiolytics; thus it may serve as a better model for the investigation of the neurobiological mechanisms of action of antipsychotic drugs and delineating the pathophysiology of schizophrenia.

1. Introduction
Recent years have witnessed a growing number of clinical studies
suggesting that antipsychotic action starts early and increases in magnitude with repeated treatment (Agid et al., 2003, 2006; Emsley et al.,
2006; Glick et al., 2006; Kapur et al., 2005; Leucht et al., 2005; Raedler
et al., 2007). For example, Agid et al. (2003) examined 42 double-blind,
comparator-controlled studies (> 7000 patients) using a meta-analysis technique. They found that psychotic symptoms improved within
the first week of treatment and showed a progressive improvement
over subsequent weeks, with the overall pattern of improvement
approximating an exponential curve. Leucht et al. (2005) analyzed a
large homogeneous database of original patient data from 7 random-

ized, double-blind studies of the efficacy of amisulpride in patients
with schizophrenia spectrum disorders and found the same results.
More improvement occurs in the first few days than in any later
period of equal duration (Leucht et al., 2005). These findings are in
contrast to the traditional held belief that the onset of antipsychotic
action is delayed and takes 2-3 weeks before the onset of therapeutic
benefits is produced (Gelder et al., 2000).
This change in our clinical understanding demands a re-examination of the currently available animal models of antipsychotic
drugs. Many models rely on the acute effects of antipsychotic treatment, including amphetamine-induced hyperlocomotion, the catalepsy and paw test to prepulse inhibition, latent inhibition, and
social interaction (Arnt, 1982; Ellenbroek et al., 1987; Hoffman and
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Donovan, 1995; Sams-Dodd, 1999; Swerdlow et al., 2000; Weiner,
2003). Because of the limitation of acute treatment regimen, none of
these models provides a relevant model of time course of antipsychotic effect. On the other hand, models that have used chronic treatment regimens, such as “depolarization block” (Grace and Bunney,
1986), antipsychotic-induced Fos expression (Robertson and Fibiger,
1992), social behavior (Sams-Dodd, 1998), or the chronic prepulse
inhibition model (Andersen and Pouzet, 2001), have often examined
behavioral or physiological changes after a certain period of treatment has elapsed (e.g., ~21 days after the first drug administration),
instead of during the chronic treatment period. Thus, they are limited in tracking changes that occur during the treatment period.
We recently developed a rat conditioned avoidance responding
model based on a repeated treatment regimen and examined its
validity in modeling the time course of antipsychotic effect (Li et al.,
2007). We found that rats repeatedly treated with haloperidol, olanzapine, or risperidone exhibited a decrease in avoidance responding
starting on the first day of treatment. Over the seven daily test sessions, their avoidance responding displayed a progressive, acrosssession decline, which recovered after treatment was stopped. In
contrast, rats treated with chlordiazepoxide or vehicle maintained
a high level of avoidance responding throughout the entire testing
period. Thus the repeated treatment conditioned avoidance responding model seems capable of mimicking several key features of clinical effects of antipsychotics, such as early-onset, progressive accumulation, asymptote, and drug-discontinuation relapse.
The present study represents another attempt to develop clinically
relevant animal models of antipsychotic activity that capture important hallmarks of clinical features of antipsychotic treatment along
the time course of antipsychotic treatment in the clinic. The objective was to investigate whether repeated antipsychotic treatment,
as opposed to anxiolytic treatment, could produce an early-onset
and progressively increased inhibitory effect on the amphetamine
or phencyclidine-induced hyperlocomotion. Both amphetamine
and phencyclidine-induced hyperlocomotion models are commonly
used as screening tools for the detection of antipsychotic activity.
When given acutely, all antipsychotics inhibit hyperlocomotor activity induced by acute administrations of amphetamine or phencyclidine (Arnt, 1995; Gleason and Shannon, 1997). However, little is
known about the effects of repeated antipsychotic treatment on the
motor activity induced by repeated amphetamine or phencyclidine
treatment.
2. Materials and methods
2.1. Animals
A total of 144 male Sprague-Dawley rats (226-250 g upon arrival,
Charles River, Portage, MI) were used. They were housed two per
cage, in 48.3 cm × 26.7 cm × 20.3 cm transparent polycarbonate cages
under 12-h light/dark conditions (light on between 6:30 am and
6:30 pm). Room temperature was maintained at 21±1° C with a relative humidity of 55-60%. Food and water were available ad libitum.
Animals were allowed at least one week of habituation to the animal facility before being used in experiments. All procedures were
approved by the Institutional Animal Care and Use Committee at
the University of Nebraska-Lincoln.
2.2. Drugs
The injection solutions of haloperidol (5 mg/ml ampoules, Sabex
Inc. Boucheville, Quebec, Canada) and chlordiazepoxide (SigmaAldrich, St. Louis, MO) were obtained by mixing drugs with sterile
water. The injection solutions of d-amphetamine sulfate (Sigma-RBI)
and phencyclidine hydrochloride (gift from National Institute on
Drug Abuse Chemical Synthesis and Drug Supply Program) were
obtained by mixing drugs with 0.9% saline. Clozapine (gift from the
NIMH drug supply program) and olanzapine (Toronto Research
Chemical Inc., Canada) were dissolved in 1.5% glacial acetic acid dis-
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tilled water. Haloperidol, clozapine, olanzapine, amphetamine and
phencyclidine were administered subcutaneously, whereas chlordiazepoxide was administered intraperitoneally.
2.3. Locomotor activity apparatus
Sixteen activity boxes were housed in a quiet room. The boxes
were 48.3 cm × 26.7 cm × 20.3 cm transparent polycarbonate cages,
which were similar to the home cages but were each equipped with a
row of 6 photocell beams (7.8 cm between two adjacent photobeams)
placed 3.2 cm above the floor of the cage. A computer detected the
disruption of the photocell beams and recorded the number of beam
breaks. All experiments were run during the light cycle.
2.4. Experiment 1: effects of repeated haloperidol and clozapine treatment
on amphetamine-induced hyperlocomotion
In this experiment, we examined the effects of repeated haloperidol and clozapine treatment on amphetamine-induced hyperlocomotion. We chose three doses of haloperidol (0.01, 0.05 and 0.10 mg/
kg) and clozapine (5, 10, and 20 mg/kg) which cover subclinical,
optimal clinical, and supra-clinical doses based on the dopamine D2
occupancy data (50%-75% occupancy) (Kapur et al., 2003a). Also, at
the medium and high doses, both haloperidol and clozapine selectively disrupt avoidance responding—a validated behavioral index
of antipsychotic activity (Li et al., 2004). The dose for amphetamine
was 1.5 mg/kg, which is the common dose used in the literature
(Arnt, 1995; Natesan et al., 2006; Sills et al., 2000).
2.5. Experimental procedure
Forty-eight rats were randomly assigned to one of eight groups (n
= 6/group): vehicle (water) + vehicle (saline, SAL), vehicle (water)
+ amphetamine, haloperidol (0.01 mg/kg) + amphetamine, haloperidol (0.05 mg/kg) + amphetamine, haloperidol (0.10 mg/kg)
+ amphetamine, clozapine (5.0 mg/kg) + amphetamine, clozapine (10.0 mg/kg) + amphetamine, and clozapine (20.0 mg/kg) +
amphetamine. After two days of habituation to the testing room
and the testing boxes (30 min/day for 2 days), on day 1, rats first
received one of the following seven subcutaneous injections: vehicle (sterile water), haloperidol 0.01, 0.05, or 0.10 mg/kg, or clozapine 5.0, 10.0, or 20.0 mg/kg. They were then immediately placed
in locomotor activity boxes for 30 min. At the end of the 30-min
period, rats were taken out and injected with either vehicle (sc)
or amphetamine (1.5 mg/kg, sc) and placed back in the boxes for
another 60 min. Locomotor activity (number of photobeam breaks)
was measured in 5 min intervals throughout the entire 90-min testing session. This procedure was repeated for another 4 days (a total
of 5 testing days).
2.6. Experiment 2: effects of repeated haloperidol and clozapine treatment
on phencyclidine-induced hyperlocomotion
Experiment 2 examined the effects of repeated haloperidol and
clozapine treatment on phencyclidine-induced hyperlocomotion.
The basic procedure was identical to that of Experiment 1 with the
exception that phencyclidine (3.2 mg/kg, sc) was used. This dose of
phencyclidine is shown to induce a robust hyperlocomotion effect
without causing severe stereotypy (Gleason and Shannon, 1997;
Kalinichev et al., 2008).
2.7. Experiment 3: effects of repeated olanzapine and chlordiazepoxide treatment on amphetamine or phencyclidine-induced hyperlocomotion
Experiment 3 examined the effects of repeated olanzapine and
chlordiazepoxide treatment on amphetamine or phencyclidine
induced hyperlocomotion. Forty-eight rats were randomly assigned
to one of seven groups (n = 6/vehicle group, n = 7 for other groups):
vehicle (water, sc or ip) + vehicle (saline, sc), vehicle (water, sc) +
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amphetamine (1.5 mg/kg, sc), vehicle (water, sc) + phencyclidine
(3.2 mg/kg, sc), olanzapine (1.0 mg/kg, sc) + amphetamine, olanzapine (1.0 mg/kg, sc) + phencyclidine, chlordiazepoxide (10.0 mg/kg,
ip) + amphetamine, and chlordiazepoxide (10.0 mg/kg, ip) + phencyclidine. The basic procedure was identical to that of Experiment 1.
We chose olanzapine 1.0 mg/kg dose because this is a clinically relevant dose in terms of its ability to disrupt conditioned avoidance
responding (Li et al., 2007), as well as to give rise to ~70% striatal D2
occupancy (Kapur et al., 2003b). We included 10.0 mg/kg chlordiazepoxide as a pharmacological control. This dose of chlordiazepoxide is ineffective in disrupting avoidance responding (Li et al., 2004,
2007; Mead et al., 2008), but it is effective in several aversively conditioned paradigms, such as Pavlovian fear conditioning and passive
avoidance responding (Burghardt et al., 2004; Joordens et al., 1998;
Klint, 1991; Mead et al., 2008).

of six antipsychotic-treated groups showed a significant upward
increase in motor activity (all Ps < 0.05, except the haloperidol 0.01
mg/kg group, F(4,20) = 1.707, P = 0.188), indicating that the inhibitory effect of haloperidol and clozapine was gradually weakened by
repeated drug administration.
This attenuation effect was most apparent with the highest dose
of haloperidol (0.10 mg/kg) and clozapine (20 mg/kg) (see Figure
1). For example, haloperidol at 0.10 mg/kg reduced amphetamineinduced hyperlocomotion by 77% on day 1, but only 54% on day 5.
Similarly, clozapine at 20.0 mg/kg reduced amphetamine-induced
hyperlocomotion by 64% on day 1, but only 31% on day 5. Percent
inhibition was calculated using this formula:

2.8. Statistical analysis

3.1.3. Repeated haloperidol and clozapine treatment shortened the time
course of the inhibitory action on amphetamine-induced hyperlocomotion
Figure 2 shows the time course (measured in 5-min blocks over
the 60-min period after amphetamine injection) of the effects of haloperidol and clozapine treatment on amphetamine-induced hyperlo-

Motor activity data from the five consecutive drug test days were
expressed as mean values ± S.E.M. and analyzed using a factorial repeated measures ANOVA with the between-subjects factor
being the treatment conditions (“Treatment,” e.g. 3 doses of haloperidol vs. vehicle), and the within-subject factor being the test days
(“Days,” e.g. day 1 test, day 2 test, etc.), followed by Post-hoc Tukey
tests to examine two-group difference. Motor activity data from each
daily test were also analyzed using a factorial repeated measures
ANOVA with the between-subjects factor being the treatment conditions (“Treatment,” e.g. 3 doses of haloperidol vs. vehicle), and the
within-subject factor being the 5-min time block (“Block,” e.g. block
for 60 min after amphetamine or phencyclidine injection). If necessary, one-way ANOVA was used to identify two-group difference.
A conventional two-tailed level of significance at the 5% level was
required.
3. Results
3.1. Experiment 1: effects of repeated haloperidol and clozapine treatment
on amphetamine-induced hyperlocomotion
3.1.1. Acute haloperidol and clozapine treatment dose-dependently inhibited the hyperlocomotion induced by amphetamine
Figure 1 shows the mean locomotor activity of the eight groups
of rats during the 60-min test period after vehicle or amphetamine
injection across the five test days. On day 1, acute haloperidol and
clozapine treatment dose-dependently inhibited the hyperlocomotion induced by amphetamine. One-way ANOVA revealed that
there was a significant main effect of “Treatment”( F(7,47) = 16.368, P <
0.001). Post-hoc Tukey tests showed that in comparison to the vehicle treatment, amphetamine produced a robust increase in motor
activity (P < 0.001). This amphetamine effect was significantly attenuated by haloperidol at 0.05 mg/kg (P = 0.006) and 0.10 mg/kg (P <
0.001) and clozapine at 10.0 and 20.0 mg/kg (P < 0.001). Low dose of
haloperidol (0.01 mg/kg) and clozapine (5.0 mg/kg) did not significantly inhibit amphetamine-induced hyperlocomotion (haloperidol
0.01 mg/kg, P = 0.999; clozapine 5.0 mg/kg, P < 0.148 vs. the vehicle
+ amphetamine group).
3.1.2. Repeated haloperidol and clozapine treatment attenuated the inhibition on the amphetamine-induced hyperlocomotion across days
Two-way repeated measures ANOVA with the treatment conditions as the between-subjects variable and testing days as the withinsubjects variable revealed a significant main effect of “Treatment”
(F(7,40) = 13.074, P < 0.001), a significant main effect of “Days” (F(4,160)
= 16.701, P < 0.001), and “Treatment” × “Days” interaction (F(28,160) =
1.965, P = 0.005). This interaction effect was attributed to the acrosssession change in the effects of repeated haloperidol and clozapine
treatments on amphetamine-induced hyperlocomotion. Over the
5 test days, repeated amphetamine treatment did not significantly
increase motor activity (F(4,20) = 1.513, P = 0.236). However, five out
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the amphetamine injection and lasted for the remainder of the test
session (all Ps < 0.001 in comparison to the vehicle + amphetamine
group). However, on day 5, although its inhibitory effect also started
at the 10-min point (P = 0.001), the inhibition only lasted about 40
min as the haloperidol 0.10 mg/kg group no longer differed significantly from the vehicle + amphetamine group on the last two 5-min
blocks (all Ps < 0.05). Similarly for clozapine, on day 1, clozapine 10
mg/kg and 20 mg/kg inhibited amphetamine-induced hyperlocomotion starting at the 10-min point (all Ps < 0.001) and lasted for
the remainder of the test session (all Ps < 0.04 one-tailed in comparison to the vehicle + amphetamine group). In contrast, on day 5, the
two clozapine groups did not differ significantly from the vehicle +
amphetamine group in any 5-min blocks except one (all Ps < 0.05
except at the 45-min point, P = 0.03 for clozapine 10 mg/kg group vs.
the vehicle + amphetamine).
3.2. Experiment 2: effects of repeated haloperidol and clozapine treatment
on phencyclidine-induced hyperlocomotion
3.2.1. Acute haloperidol and clozapine treatment dose-dependently inhibited the hyperlocomotion induced by phencyclidine
Figure 3 shows the mean locomotor activity of the eight groups of
rats during the 60-min period after vehicle or phencyclidine injection across the five test days. On day 1, acute haloperidol and clozapine treatment dose-dependently inhibited phencyclidine-induced
hyperlocomotion. One-way ANOVA revealed that there was a significant main effect of “Treatment” (F(7,47) = 27.203, P < 0.001). Posthoc Tukey tests showed that in comparison to the vehicle treatment,

comotion on the first and last day of drug testing (excluding the
vehicle + vehicle group). It appears that with repeated treatment,
haloperidol and clozapine shortened its inhibition on amphetamineinduced hyperlocomotion. For example, on day 1, the inhibitory
effect of haloperidol 0.10 mg/kg started at the 10-min point after
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phencyclidine produced a robust increase in motor activity (P <
0.001). This phencyclidine effect was significantly attenuated by
haloperidol at 0.05 mg/kg (P = 0.016) and 0.10 mg/kg (P = 0.002)
and clozapine at all three doses (all Ps < 0.002). Low dose of haloperidol (0.01 mg/kg) did not significantly inhibit phencyclidineinduced hyperlocomotion (haloperidol 0.01 mg/kg, P = 1.00).
3.2.2. Repeated haloperidol and clozapine treatment potentiated the inhibition on phencyclidine-induced hyperlocomotion across days
Two-way repeated measures ANOVA with treatment conditions
as the between-subjects variable and test days as the within-subjects
variable revealed a significant main effect of “Treatment” (F(7,40) =
44.577, P < 0.001), a significant main effect of “Days” (F(4,160) = 5.079,
P = 0.001), and “Treatment” × “Days” interaction (F(28,160) = 4.035, P
< 0.001). This interaction effect was attributed to the across-session
change in the effects of repeated haloperidol and clozapine treatment on phencyclidine-induced hyperlocomotion. Throughout the
5 test days, repeated phencyclidine treatment significantly increased
motor activity (F(4,20) = 4.080, P = 0.014), indicating a phencyclidineinduced behavioral sensitization. Despite this, repeated treatment
of haloperIdol and clozapine progressively strengthened their ability to inhibit phencyclidine-induced hyperlocomotion. Across the 5
drug test days, four out of six antipsychotic-treated groups showed
a significant decrease in motor activity (all Ps < 0.05, except the haloperidol 0.01 mg/kg group, F(4,20) = 0.804, P = 0.537 and clozapine 10
mg/kg group, F(4,20) = 0.523, P = 0.720). This potentiated inhibition
was most apparent in the haloperidol 0.10 mg/kg group and clozapine 5.0 mg/kg group. For example, haloperidol at 0.10 mg/kg
reduced phencyclidine-induced hyperlocomotion by 42% on day 1,
but 89% on day 5. Similarly, clozapine at 5.0 mg/kg reduced phencyclidine-induced hyperlocomotion by 42% on day 1, but up to 66%
on day 5.
3.2.3. Repeated haloperidol and clozapine treatment prolonged the time
course of the inhibitory action on phencyclidine-induced hyperlocomotion
Figure 4 shows the time course (measured in 5-min blocks for the
60-min period after phencyclidine injection) of the effects of haloperidol and clozapine treatment on phencyclidine-induced hyperlocomotion on the first and last day of drug testing (excluding the
vehicle + vehicle group). It appears that with repeated treatment,
haloperidol and clozapine advanced or prolonged their inhibition
on phencyclidine-induced hyperlocomotion. For example, on day 1,
the inhibitory effect of haloperidol 0.10 mg/kg started at the 20-min
point after the phencyclidine injection, and lasted for the remainder
of the test session (all Ps < 0.05 in comparison to the vehicle + phencyclidine group except at the 25-min point Ps < 0.05). On day 5, its
inhibitory effect started at the 10-min point (P = 0.008), and lasted for
the remainder of the test session (all Ps < 0.001 in comparison to the
vehicle + phencyclidine group except at the 10-min point P = 0.008).
Similarly for clozapine, on day 1, clozapine 5.0 mg/kg inhibited
the phencyclidine-induced hyperlocomotion starting at the 20-min
point (P < 0.05), and lasted for the remainder of the test session (all
Ps < 0.05). On day 5, clozapine 5 mg/kg inhibited the phencyclidineinduced hyperlocomotion starting at the 10-min point, and lasted for
the remainder of the test session (all Ps < 0.001).
3.3. Experiment 3: effects of repeated olanzapine and chlordiazepoxide treatment on amphetamine or phencyclidine-induced hyperlocomotion
3.3.1. Acute olanzapine and chlordiazepoxide treatment inhibited the
hyperlocomotion induced by amphetamine, but only olanzapine inhibited
the hyperlocomotion induced by phencyclidine
Figure 5 shows the mean locomotor activity of the seven groups
of rats during the 60-min period after amphetamine (Figure 5A) or
phencyclidine (Figure 5B) injection across the five test days. On day
1, one-way ANOVA analysis revealed a significant main effect of
“Treatment” (F(2,20) = 12.237, P < 0.001). Post-hoc Tukey tests showed

that in comparison to the vehicle treatment, amphetamine produced
a robust increase in motor activity (P < 0.001). Olanzapine at 1.0 mg/
kg and chlordiazepoxide at 10.0 mg/kg significantly inhibited the
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amine-induced hyperlocomotion throughout five test days (Posthoc Tukey two-group comparisons: olanzapine vs. amphetamine, P
< 0.001, chlordiazepoxide vs. amphetamine, P < 0.001). Although the
effect of olanzapine persisted throughout the 5 test days, it should
be noted that the average inhibition of olanzapine on amphetamineinduced hyperlocomotion decreased from 45.5% on day 1 to 29.9%
on day 5 (Figure 6E). In contrast, the effect of chlordiazepoxide on
amphetamine-induced hyperlocomotion was relatively stable. Twoway repeated measures ANOVA on the data from the chlordiazepoxide rats revealed no significant main effectof “Days” (F(4,24) = 0.410,
P = 0.800). For the phencyclidine-induced hyperlocomotion, twoway repeated measures ANOVA showed a significant main effect
of “Treatment” (F(2,18) = 8.921, P = 0.002), a significant main effect of
“Days” (F(4,72) = 4.218, P = 0.004), and “Treatment” × “Days” interaction (F(8,72) = 2.958, P = 0.006). Inspection of Figure 6E and F suggests that repeated treatment of olanzapine potentiated inhibition
on phencyclidine-induced hyperlocomotion across the 5 test days as
the per cent inhibition changed from 31% on day 1 to 53% on day 5,
whereas chlordiazepoxide tended to lose its inhibition (19% on day
1, and 9% on day 5).
To better understand the behavioral patterns of all the drugs
tested in this study on amphetamine and phencyclidine-induced
hyperlocomotion, we summarized the results from all three experiments and used the per cent inhibition on each day as a measure
of a drug's efficacy. As can be seen in Figure 6, with repeated treatment, haloperidol, clozapine and olanzapine all gradually lost their
ability to inhibit amphetamine-induced hyperlocomotion as there
was a steady decrease in % inhibition, whereas their ability to inhibit
phencyclidine-induced hyperlocomotion progressively increased
across sessions (Figure 6A-E). In contrast, chlordiazepoxide (Figure 6F) exhibits no impact on phencyclidine-induced hyperlocomotion. Figure 7 shows the per cent inhibition changes from day 1
to day 5 for all antipsychotics tested in this study. On day 1, haloperidol and olanzapine show a higher efficacy in inhibiting amphetamine-induced hyperlocomotion than phencyclidine-induced one,
whereas clozapine shows the opposite effect. Clozapine is more efficacious in inhibiting phencyclidine-induced hyperlocomotion than
amphetamine-induced one (Figure 7). However, on day 5, all three
drugs had a higher per cent inhibition on phencyclidine-induced
hyperlocomotion than on amphetamine-induced hyperlocomotion.
This change was due to an increase of per cent inhibition on phencyclidine-induced hyperlocomotion and a decrease of inhibition on
amphetamine-induced hyperlocomotion from day 1 to day 5.
hyperlocomotion induced by amphetamine, as there was a significant group difference between the amphetamine and olanzapine
group (P < 0.001) and between the amphetamine and chlordiazepoxide group (P = 0.006). On phencyclidine-induced hyperlocomotion,
one-way ANOVA revealed a significant main effect of “Treatment”
(F(2,20) = 4.111, P = 0.034). Post-hoc Tukey tests showed that in comparison to the vehicle treatment, phencyclidine produced a robust
increase in motor activity (P < 0.001). Our data also showed that only
olanzapine significantly attenuated the acute effect of phencyclidine,
as indicated by the finding that only the olanzapine group significantly differed from the phencyclidine group (P = 0.027), but the
chlordiazepoxide group did not (P = 0.229).
3.3.2. Repeated olanzapine, but not chlordiazepoxide treatment attenuated
inhibition on amphetamine-induced hyperlocomotion across days, but significantly potentiated inhibition on phencyclidine-induced hyperlocomotion
For amphetamine-induced hyperlocomotion, two-way repeated
measures ANOVAs with treatment conditions (e.g. vehicle, olanzapine or chlordiazepoxide) as the between-subjects variable and test
days as the within-subjects variable revealed a significant main effect
of “Days” (F(4,72) = 3.139, P = 0.019) and a significant main effect of
“Treatment” (F(2,18) = 22.052, P < 0.001), but no significant “Treatment”
× “Days” interaction (F(8,72) = 0.967, P = 0.469). Repeated treatment
of olanzapine and chlordiazepoxide significantly inhibited amphet-

4. Discussion
Using two well-established hyperlocomotion models, we examined and compared the effects of repeated antipsychotic treatment
on hyperlocomotion induced by repeated amphetamine and phencyclidine treatment in an attempt to develop clinically relevant animal models of antipsychotic drugs that can capture the time course
of antipsychotic action, e.g., an early-onset and progressively
increased effect over time. Results show that both typical (haloperidol) and atypical (clozapine, olanzapine) antipsychotics acutely
inhibited phencyclidine-induced hyperlocomotion and progressively enhanced this inhibitory effect over the repeated treatment
period. In contrast, an anxiolytic drug chlordiazepoxide did not
show this pattern of action. Repeated chlordiazepoxide treatment
gradually attenuated its inhibition on phencyclidine-induced hyperlocomotion. Although antipsychotic drugs also acutely inhibited
amphetamine-induced hyperlocomotion, so did chlordiazepoxide,
thus it is impossible to distinguish antipsychotics from chloridiazepoxide on the basis of this action. In addition, repeated antipsychotic treatments gradually lost their inhibition on amphetamineinduced hyperlocomotion. Based on these findings, we suggest that
the repeated phencyclidine-induced hyperlocomotion model may
be better than the repeated amphetamine model in detecting antipsychotic action, capturing the time course of antipsychotic effect and
differentiating antipsychotics from anxiolytics.
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In the majority of antipsychotic drug studies using both hyperlocomotion models, the effects of antipsychotic drugs and other experimental drugs are often tested after a single injection and efforts
have been devoted to understanding the neurochemical mechanisms underlying amphetamine and phencyclidine-induced behavioral effects and effects of antipsychotics on both types of hyperlocomotion. All antipsychotics acutely inhibit motor activation effect of
amphetamine and phencyclidine (Abekawa et al., 2007; Arnt, 1995;
Millan et al., 1999, 2008). Antipsychotics with preferential action
on D2 receptors such as haloperidol, fluphenazine, cis(Z)flupentixol, amisulpride, eticlopride, and raclopride all show a preferential
inhibitory effect on amphetamine-induced hyperlocomotion over
phencyclidine-induced one, whereas atypicals such as clozapine and
olanzapine, which are mixed D2-like/5-HT2A antagonists, have an
opposite effect, showing a preferential inhibition on phencyclidineinduced hyperlocomotion (Gleason and Shannon, 1997; MaurelRemy et al., 1995; Millan et al., 1999). Other 5-HT2A antagonists such
as LY53857, ritanserin, ketanserin, fananserin, and MDL100,907, but
not 5-HT1A or 5-HT3 antagonists such as WAY 100,635 and zatosetron,
also block phencyclidine-induced hyperlocomotion (Gleason and
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Shannon, 1997; Millan et al., 1999). Depletion of 5-HT in the nucleus
accumbens by parachloroamphetamine abolishes phencyclidineinduced hyperlocomotion (Millan et al., 1999). These findings suggest
that inhibition of amphetamine-induced hyperlocomotion is primarily mediated by the antagonistic action on dopamine D2 receptors,
whereas inhibition of phencyclidine-induced hyperlocomotion is
primarily due to multiple actions of antipsychotics on dopamine D2
and 5-HT2A receptors, as well as perhaps other molecular sites (Gleason and Shannon, 1997; Maurel-Remy et al., 1995; Millan et al., 1999).
Our results are in agreement with these previous reports except that
we did not find that acute olanzapine shows a preferential effect on
phencyclidine-induced hyperlocomotion (Millan et al., 1999). This
discrepancy may be due to methodological differences such as the
phencyclidine doses used in these studies. Millan et al. (1999) used 20.0
mg/kg, whereas we used 3.2 mg/kg. Also, the testing apparatuses
were different. Millan et al. (1999) used testing chambers equipped
with 2 infrared beams, whereas we used testing boxes equipped
with 6 sets of photobeams. Thus, differential effects of typical and
atypical antipsychotics on amphetamine or phencyclidine-induced
hyperlocomotion might depend on the specific testing conditions.

Repeated Antipsychotic Treatment

and

H y p e r l o c o m o t i o n 								

Although acute amphetamine and phencyclidine hyperlocomotion models are useful in delineating the neurobiological mechanisms of action of psychotherapeutic and psychomimetic drugs,
they are limited in their ability to capture the intrinsic antipsychotic
efficacy of a drug and mimic the time course of antipsychotic treatment in the clinic (Agid et al., 2003; Leucht et al., 2005) because inhibition of amphetamine or phencyclidine-induced hyperlocomotion
is not exclusively the property of antipsychotics (Arnt, 1995; Gleason and Shannon, 1997; Millan et al., 1999). In the present study, we
employed a repeated treatment schedule for both psychotomimetic
drugs and antipsychotic drugs. We found some interesting effects
not reported before. First, repeated haloperidol, clozapine, or olanzapine treatment all progressively potentiate inhibition on phencyclidine-induced hyperlocomotion across sessions and prolongs this
action within sessions, whereas their inhibition on amphetamineinduced hyperlocomotion is gradually attenuated across sessions
and shortened within sessions. Second, repeated chlordiazepoxide
treatment retains its inhibition on amphetamine-induced hyperlocomotion, and tends to decrease its inhibition on phencyclidineinduced hyperlocomotion; thus, it shows a behavioral profile distinct from all antipsychotics. Interestingly, antidepressants such
as fluoxetine and citalopram also exhibit a behavioral profile distinctive from that of antipsychotics. Acute fluoxetine or citalopram
increases amphetamine-induced hyperlocomotion (Fletcher et al.,
2006; Millan et al., 2003) but has no effect on phencyclidine-induced
model (Redmond et al., 1999). Repeated fluoxetine or citalopram
treatment tends to enhance amphetamine-induced hyperlocomotion
(Arnt et al., 1984; Sills et al., 1999, 2000) and phencyclidine-induced
hyperlocomotion (Redmond et al., 1999). Taken together, a combination of repeated amphetamine and phencyclidine hyperlocomotion
models may be utilized to distinguish anxiolytics and antidepressants from antipsychotics.
The present study provides another perspective to evaluate the
validity of amphetamine versus phencyclidine model as a model
of schizophrenia. Suggestions have been made that phencyclidine
model is better than amphetamine model because only NMDA
antagonists such as ketamine and phencyclidine can induce neurocognitive deficits and negative symptoms in human and animal subjects resembling those seen in patients with schizophrenia
(Javitt and Zukin, 1991; Sams-Dodd, 1998). In contrast, patterns of
symptoms induced by amphetamine differ markedly from those
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seen in schizophrenia (Krystal et al., 2005). In the present study, we
found that only the inhibitory effect of repeated antipsychotic treatment on phencyclidine-induced hyperlocomotion mimics the time
course of action of antipsychotics in the clinic (e.g. early onset, progressively increasing) (Agid et al., 2003), suggesting that phencyclidine-induced hyperlocomotion may be a valid index of schizophrenia-like psychosis. These results also suggest that repeated
phencyclidine-induced hyperlocomotion model based on a repeated
antipsychotic treatment regimen is better than amphetamine model
in mimicking antipsychotic effcts as seen in the clinic. This point is
particularly important for clozapine, as tolerance, rather than a progressively enhanced effect (e.g. sensitization) is often observed with
chronic treatment in animals (Goudie et al., 2007a,b). Thus, many
researchers have been forced to model this tolerance effect as clozapine’s antipsychotic effect in the clinic, which tends to increase
over time (Kane et al., 1988; Meltzer et al., 2003). To our best knowledge, inhibition of repeated phencyclidine-induced hyperlocomotion is the only measure that captures the clinical-like pattern of clozapine treatment (e.g. a progressively increased effect); thus, it may
reflect the “true” antipsychotic action seen in schizophrenic patients.
In this regard, this model is an important addition to the existing
animal models based on repeated antipsychotic treatment (Li et al.,
2007), and thus may serve as a valid model to investigate the neurochemical and neural mechanisms of action of antipsychotic drugs
and search for new antipsycotic drugs with novel mechanisms of
action.
So then, what mechanism(s) can account for the progressively
enhanced inhibition of repeated antipsychotic treatment on phencyclidine-induced hyperlocomotion? The mechanism of action of
phencyclidine is complex (Jentsch and Roth, 1999). Besides blocking NMDA receptor channels, phencyclidine can enhance serotonergic, dopaminergic and glutamatergic neurotransmission in the
nucleus accumbens and prefrontal cortex (Abekawa et al., 2007;
Maurel-Remy et al., 1995; Millan et al., 1999). Based on the findings that acute 5-HT2A antagonists selectively inhibit phencyclidine-induced hyperlocomotion (Gleason and Shannon, 1997), that
repeated administration of clozapine attenuates phencyclidineinduced hyperlocomotion even 11 days after the last administration of clozapine (Abekawa et al., 2007) and causes a down-regulation of 5-HT2A receptors in the prefrontal cortex (Doat-Meyerhoefer
et al., 2005), as well as the finding that microinjection of phencyclidine into the prefrontal cortex elicits hyperlocomotion (Abekawa et
al., 2007), we speculate that antipsychotics may enhance their inhibition on phencyclidine-induced hyperlocomotion by down-regulating 5-HT2A receptors and concomitantly decreasing phencyclidineinduced dopamine and 5-HT increases in the prefrontal cortex. On
the other hand, because repeated phencyclidine treatment can also
induce neurotoxic effects consisting of vacuole formation in pyramidal neurons in several corticolimbic brain regions including the posterior cingulate and retrosplenial cortices (Ellison, 1994; Ellison and
Switzer, 1993; Olney et al., 1989, 1999), and antipsychotic drugs such
as haloperidol, clozapine and olanzapine can effectively block the
neurotoxic action of phencyclidine or MK-801 (Farber et al., 1996,
1993; Olney and Farber, 1995) and significantly attenuate sensitization elicited by phencyclidine (Phillips et al., 2001), thus, one cannot exclude the possibility that repeated antipsychotic treatment
may enhance its inhibition on phencyclidine-induced hyperlocomotion by progressively improving its efficacy on prevention of vacuole formation in pyramidal neurons in the corticolimbic regions.
This issue needs further investigation, and the outcome of this line
of research may shed light on the pathophysiology of schizophrenia
and the molecular mechanisms responsible for antipsycotic action.
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